This paper reports the following 60-week data from the UNCOVER-2 and UNCOVER-3 trials, as well as 12-week and 60-week data from a third phase 3 trial, UNCOVER-1:
• In the UNCOVER-1 trial, at week 12, patients had better responses to ixekizumab than to placebo: in 2-week dosing group, 81.8% had a static Physicians Global Assessment (sPGA) score of 0 (clear) or 1 (minimal psoriasis) and 89.1% had a PASI 75 response; in 4-week dosing group, the respective rates were 76.4% and 82.6%; and in placebo group, the rates were 3.2% and 3.9% (p<0.001 for all comparisons of ixekizumab vs. placebo).
• In the UNCOVER-1 and UNCOVER-2 trials, among patients who were randomly reassigned at week 12 to receive 80 mg of ixekizumab every 4 or 12 weeks, or placebo, an sPGA score of 0 or 1 was maintained by 73.8%, 39.0%, and 7.0% of the patients, respectively.
• Patients in the UNCOVER-3 trial received continuous treatment of ixekizumab from weeks 0 through 60, and at week 60, at least 73% had sPGA score of 0 or 1 and at least 80% had a PASI 75 response.
• Adverse events reported during ixekizumab use included neutropenia, candidal infections, and inflammatory bowel disease.